Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus rating of “Buy” from the twelve research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $136.88.
A number of analysts have issued reports on ASND shares. Canaccord Genuity raised their target price on Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. Wedbush reaffirmed a “buy” rating and issued a $223.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, June 28th. Zacks Investment Research downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. Finally, BidaskClub downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Monday, June 24th.
Shares of ASND traded up $0.62 during midday trading on Wednesday, reaching $114.77. The company had a trading volume of 67,984 shares, compared to its average volume of 337,259. Ascendis Pharma A/S has a 1-year low of $53.21 and a 1-year high of $133.96. The company has a market capitalization of $4.84 billion, a PE ratio of -30.69 and a beta of 0.62. The business has a 50 day simple moving average of $114.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 22.32 and a current ratio of 22.32.
Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, May 30th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.44). Ascendis Pharma A/S had a negative return on equity of 34.64% and a negative net margin of 901.89%. The company had revenue of $6.15 million during the quarter, compared to analyst estimates of $0.66 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -5.46 EPS for the current year.
Large investors have recently modified their holdings of the stock. NumerixS Investment Technologies Inc acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth about $94,000. Private Ocean LLC acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth about $113,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth about $128,000. Tobam acquired a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth about $157,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth about $204,000.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Further Reading: What is a conference call?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.